Clinical Trials

Are you an adult with heart failure and an implanted CardioMEMS pulmonary artery pressure (PAP) monitor? This study is investigating whether psychological stress can make the symptoms of heart failure worse. Participants of this study will have their blood pressure monitored and their blood drawn after undergoing mental stress in a controlled setting, within a laboratory. To participate in this study, you must be at least 18 years old. This study takes place in New Haven, Connecticut.

Do you have heart failure and need treatment with intravenous (IV) diuretics? This study is exploring the use of chloride supplementation in people with heart failure who require treatment with IV diuretics, which are used to help rid your body of excess water and salt. To participate in this study, you must have heart failure with signs of volume overload (rales, edema, elevated jugular venous pressure [JVP], or weight gain of at least 5 pounds) requiring treatment with IV diuretics. This study takes place in New Haven, Connecticut.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Have you been diagnosed with obstructive sleep apnea (OSA) and been referred to the Yale New Haven Hospital Sleep Center for continuous positive airway pressure (CPAP) treatment? This study is examining how the features that can raise or lower the risk of OSA can impact how well CPAP works in an individual. Researchers will use detailed sleep studies to determine which features contribute to OSA. Results from this study will help researchers develop treatment plans that can lead to personalized OSA treatments to improve patient lives. To participate in this study, you must be at least 19 years old. This study takes place in North Haven, Connecticut.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have Friedrich's Ataxia? This study is looking into a supplement in the form of vitamin B3 plus exercise can help the body better use oxygen for people with Friedrich’s Ataxia. You must be 10 to 40 years old to join. Participants may be asked to take the daily supplement, exercise, or do both during the study. The study is taking place in Philadelphia, Pennsylvania.

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.